Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4277939 | 0.95 | SLC6A3 (0.36) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL4276400 | 0.92 | SLC6A3 (0.39) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL4287361 | 0.85 | SLC6A3 (0.40) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL4280008 | 0.81 | SLC6A3 (0.39) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL4278623 | 0.77 | SLC6A3 (0.41) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL4283420 | 0.76 | SLC6A3 (0.40) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL4130314 | 0.67 | CARM1 (0.50) | ACHE | |
| SCHEMBL3412801 | 0.67 | BDKRB1 (0.54) | — | |
| SCHEMBL4112400 | 0.67 | CARM1 (0.40) | SLC6A3ACHE | |
| SCHEMBL3410837 | 0.66 | BDKRB1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253669-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | SLC6A3 1698/4885SLC6A2 1720/4885SLC6A4 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.